<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051736</url>
  </required_header>
  <id_info>
    <org_study_id>ChinaNBG</org_study_id>
    <nct_id>NCT04051736</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Sabin-IPV Replacement Vaccination</brief_title>
  <official_title>a Randomized, Controlled Clinical Trial of Immunogenicity and Safety of Sabin-based Inactivated Polio Vaccine Replacing Salk-based Inactivated Polio Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Institute of Biological Products Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study replaced the 2nd and 3rd dose of Salk-IPV (produced by Sanofi) with Sabin-IPV&#xD;
      (produced by CNBG) and then reviewed the safety and immunogenicity of the vaccination, aiming&#xD;
      to acquire scientific evidence for the feasibility of immunization involving different viral&#xD;
      strains replacement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is required by China Food and Drug Administration (CFDA) that considering in the real&#xD;
      situation IPV receivers may be immuned by different viral strains of this vaccine, a phase 4&#xD;
      clinical trial aiming to demonstrate the safety and immunogenicity of the immunization&#xD;
      schedule should be carried out. To be specific, the subjects were divided into 2 groups.&#xD;
&#xD;
      Group 1 received Salk-IPV+Sabin-IPV+Sabin-IPV respectively at the age of 2,3,4 months old.&#xD;
&#xD;
      Group 2 received Salk-IPV+Salk-IPV+Salk-IPV respectively at the age of 2,3,4 months old.&#xD;
&#xD;
      Blood sample was collected before vaccination and 30 days after the third dose of&#xD;
      vaccination. Neutralization antibody against type I, Type II and Type III poliomyelitis virus&#xD;
      were detected to evaluate the seroprotection rates and antibody geometric mean&#xD;
      concentrations. The safety of both immunization schedule will also been monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 28, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>4 months</time_frame>
    <description>determine the seroconversion rate of both groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers</measure>
    <time_frame>4 months</time_frame>
    <description>Measure neutralizing antibody titers against poliovirus type I, II and III</description>
  </secondary_outcome>
  <other_outcome>
    <measure>number of participants who experience adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>analyse the number and rate of vaccine participants who have adverse events following immunization</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Vaccination</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Polio Vaccine</intervention_name>
    <description>Inactivated Polio Vaccine at age of 2,3,4 months old, respectively</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects aged from 60 days to 89 days old at the date of recruitment;&#xD;
&#xD;
          -  with informed consent signed by parent(s) or guardians;&#xD;
&#xD;
          -  parent(s) or guardians are able to attend all planned clinical appointments and obey&#xD;
             and follow all study instructions;&#xD;
&#xD;
          -  subjects did not receive any vaccines within 14 days;&#xD;
&#xD;
          -  axillary temperature ≤37.0℃&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergic to any ingredient of vaccine or with allergy history to any vaccine;&#xD;
&#xD;
          -  acute febrile disease or infectious disease;&#xD;
&#xD;
          -  serious chronic diseases;&#xD;
&#xD;
          -  any other factor that makes the investigator determines the subject is unsuitable for&#xD;
             this study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang WU</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Center for Disease Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

